CIRP and Cathepsin B in Neuroinflammation After Intracerebral Hemorrhage

NCT07665255 | Not Yet Recruiting DMC

• 2 other identifiers: XWH-7262054-ICH7262054
• Study Type: observational
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a single-center, investigator-initiated, prospective observational case-control study. Patients with intracerebral hemorrhage and healthy controls will be enrolled at Xuanwu Hospital, Capital Medical University. Peripheral venous blood samples will be collected for measurement of CIRP, Cathepsin B, and related inflammatory biomarkers. Clinical and imaging data will also be collected in the intracerebral hemorrhage group. The study aims to compare biomarker levels between patients with intracerebral hemorrhage and healthy controls and to explore the potential role of these biomarkers in neuroinflammation after intracerebral hemorrhage. No investigational treatment will be administered.

Conditions

Intracerebral Hemorrhage; Nontraumatic Intracerebral Hemorrhage

Keywords

Neuroinflammation; cirp; Cathepsin B

Outcome Measures

Primary Outcomes (1)

• Peripheral Blood CIRP Level

  Comparison of peripheral blood CIRP levels between the intracerebral hemorrhage group and the healthy control group.

  Within 24 hours after enrollment for the intracerebral hemorrhage group; once at baseline on the day of blood collection for healthy controls.

Study Arms (2)

Intracerebral Hemorrhage Group

Adults with intracerebral hemorrhage confirmed by head CT or MRI, admitted within 24 hours after symptom onset, and prospectively enrolled after informed consent. Peripheral venous blood samples (4-5 mL) will be collected, and clinical and imaging data will also be obtained.

Other: Blood Sample Collection

Healthy Control Group

Age-eligible healthy controls recruited prospectively from the hospital health examination center after informed consent. One peripheral venous blood sample (4-5 mL) will be collected, together with basic demographic and health-related information.

Other: Blood Sample Collection

Interventions

Blood Sample Collection OTHER

Peripheral venous blood sample collection for biomarker measurement only; no investigational treatment is administered.

Healthy Control Group; Intracerebral Hemorrhage Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults with intracerebral hemorrhage admitted to Xuanwu Hospital, Capital Medical University, and age-eligible healthy controls recruited from the hospital health examination center. The intracerebral hemorrhage group includes patients with supratentorial, non-surgical intracerebral hemorrhage confirmed by CT or MRI and admitted within 24 hours after symptom onset. The healthy control group includes adults without stroke or other major neurological diseases.

You may qualify if:

• Intracerebral hemorrhage group:
• Age 18 years or older Diagnosis of intracerebral hemorrhage confirmed by head CT or MRI Supratentorial hemorrhage No surgical treatment Hematoma volume less than 30 mL Admission within 24 hours after symptom onset The participant or the legally authorized representative/next of kin is able to provide written informed consent
• Healthy control group:
• Age 18 years or older Recruited from the hospital health examination center No history of stroke, intracerebral hemorrhage, cerebral infarction, or other major neurological diseases No severe active infection, severe immune disease, hematologic disease, or end-stage severe heart, liver, or renal failure No acute infection, trauma, or other obvious stress state within the previous 2 weeks Able to provide written informed consent

You may not qualify if:

• Intracerebral hemorrhage group:
• Traumatic intracerebral hemorrhage Secondary intracerebral hemorrhage caused by brain tumor, cerebrovascular malformation, aneurysm, or hemorrhagic transformation of infarction Severe active infection, severe immune disease, or hematologic disease End-stage severe heart, liver, or renal failure Pregnant or lactating women Any other condition judged unsuitable by the investigator
• Healthy control group:
• History of stroke, intracranial hemorrhage, brain tumor, or other major neurological diseases Severe active infection, severe immune disease, or hematologic disease End-stage severe heart, liver, or renal failure Pregnant or lactating women Any other condition judged unsuitable by the investigator

Sponsors & Collaborators

• Xuanwu Hospital, Beijing: lead

Biospecimen

Retention: SAMPLES WITHOUT DNA

Peripheral venous blood samples (4-5 mL per participant), including residual clinical blood samples when available, will be retained. Samples will be coded, centrifuged, aliquoted, and stored at low temperature for measurement of CIRP, Cathepsin B, and related inflammatory biomarkers.

MeSH Terms

Conditions

Cerebral Hemorrhage; Neuroinflammatory Diseases

Condition Hierarchy (Ancestors)

Intracranial Hemorrhages; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Inflammation

Central Study Contacts

Guohua Wang, MD, PhD

CONTACT

+86 13581749398; wangguohua@xwhosp.org

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 15, 2026
• First Posted: June 24, 2026
• Study Start: July 1, 2026
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): December 31, 2028
• Last Updated: June 24, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share